Many malignant cells secrete transforming growth factor-β (TGF-β), a potent immunosuppresant, suggesting that TGF-β production may represent a significant tumor escape mechanism from host immunosurveillance. Establishment of a leukocyte subpopulation with disrupted TGF-β signaling in the tumor-bearing host offers a potential means for immunotherapy of cancer. Downregulation of TGF-β secretion in tumor cells results in restoration of immunogenicity in the host, while T-cell insensitivity to TGF-β results in accelerated differentiation and autoimmunity, elements of which may be required in order to combat self-antigen-expressing tumors in a tolerized host. The rationale, approaches, and potential pitfalls of this strategy will be discussed. (C) 2000 Wiley-Liss, Inc.
|Original language||English (US)|
|Number of pages||6|
|State||Published - Oct 16 2000|
- Transforming growth factor-β
- Tumor immunosurveillance
ASJC Scopus subject areas